惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

博客园_首页
Vercel News
Vercel News
月光博客
月光博客
S
SegmentFault 最新的问题
A
About on SuperTechFans
Microsoft Security Blog
Microsoft Security Blog
U
Unit 42
Google DeepMind News
Google DeepMind News
Engineering at Meta
Engineering at Meta
B
Blog RSS Feed
Y
Y Combinator Blog
云风的 BLOG
云风的 BLOG
N
Netflix TechBlog - Medium
小众软件
小众软件
WordPress大学
WordPress大学
G
Google Developers Blog
Recent Announcements
Recent Announcements
H
Hackread – Cybersecurity News, Data Breaches, AI and More
P
Proofpoint News Feed
Blog — PlanetScale
Blog — PlanetScale
MongoDB | Blog
MongoDB | Blog
F
Fortinet All Blogs
博客园 - 【当耐特】
I
InfoQ

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A I...
2026-04-14 · via All Articles on Seeking Alpha

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis April 13, 2026 8:00 AM EDT

Company Participants

Eric McIntyre - Vice President of Finance & Investor Relations
Cameron Turtle - CEO & Director
Deanna Nguyen - Senior Vice President of Clinical Development

Conference Call Participants

Samuel Slutsky - LifeSci Capital, LLC, Research Division
Tyler Van Buren - TD Cowen, Research Division
Akash Tewari - Jefferies LLC, Research Division
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division
Min Lee - Guggenheim Securities, LLC, Research Division
Thomas Smith - Leerink Partners LLC, Research Division
Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division
David Nierengarten - Wedbush Securities Inc., Research Division
Julian Harrison - BTIG, LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Yanan Zhu - Wells Fargo Securities, LLC, Research Division
David Hoang - Deutsche Bank AG, Research Division
Brandon Frith - Wolfe Research, LLC

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Spyre Therapeutics SPY001 Part A Induction Topline Results Conference Call. [Operator Instructions] Please note that today's conference is being recorded. I will now hand the conference over to your speaker host for today, Eric McIntyre, SVP of Investor Relations. Please go ahead.

Eric McIntyre
Vice President of Finance & Investor Relations

Thank you, Olivia, and thank you all for joining. We're thrilled to be speaking with you this morning. As you saw today, we issued a press release outlining positive topline induction results from Part A of our SKYLINE trial of 001 for the treatment of moderately to severely active ulcerative colitis.

Press release and slides that we will be using today during our call are available on the Investors section of our website. I would remind everyone that during this call, we'll be making forward-looking statements related to our current expectations